282 related articles for article (PubMed ID: 25848912)
21. Serum Matrix Metalloproteinases and Left Atrial Remodeling-The Hoorn Study.
Linssen PBC; Brunner-La Rocca HP; Schalkwijk CG; Beulens JWJ; Elders PJM; van der Heijden AA; Slieker RC; Stehouwer CDA; Henry RMA
Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668720
[TBL] [Abstract][Full Text] [Related]
22. Plasma levels of tissue inhibitor of metalloproteinase-1 in patients with type 1 diabetes mellitus associate with early diabetic neuropathy and nephropathy.
Papadopoulou-Marketou N; Whiss PA; Eriksson AC; Hyllienmark L; Papassotiriou I; Wahlberg J
Diab Vasc Dis Res; 2021; 18(2):14791641211002470. PubMed ID: 33775157
[TBL] [Abstract][Full Text] [Related]
23. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans.
Dellalibera-Joviliano R; Jacob-Ferreira AL; Joviliano EE; Tanus-Santos JE; Evora PR
Vasc Med; 2012 Apr; 17(2):73-8. PubMed ID: 22402936
[TBL] [Abstract][Full Text] [Related]
24. Metalloproteinases in diabetics and nondiabetics during acute coronary syndromes and after 3 months.
Derosa G; Cicero AF; Scalise F; Avanzini MA; Tinelli C; Peros E; Fogari E; D'Angelo A
Endothelium; 2007; 14(4-5):175-83. PubMed ID: 17922333
[TBL] [Abstract][Full Text] [Related]
25. The association of vascular endothelial growth factor, metalloproteinases and their tissue inhibitors with cardiovascular risk factors in the metabolic syndrome.
Erman H; Gelisgen R; Cengiz M; Tabak O; Erdenen F; Uzun H
Eur Rev Med Pharmacol Sci; 2016; 20(6):1015-22. PubMed ID: 27049251
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
[TBL] [Abstract][Full Text] [Related]
27. Serum Matrix Metalloproteinase-9, Tissue Inhibitor of Metalloproteinase-1 and Matrix Metalloproteinase-9/ Neutrophil Gelatinase-associated Lipocalin Complex Levels in Patients With Early-stage Diabetic Nephropathy.
Cakirca G; Turgut FH
Iran J Kidney Dis; 2018 Oct; 12(5):299-304. PubMed ID: 30367022
[TBL] [Abstract][Full Text] [Related]
28. Elevated Plasma Levels of MMP-12 Are Associated With Atherosclerotic Burden and Symptomatic Cardiovascular Disease in Subjects With Type 2 Diabetes.
Goncalves I; Bengtsson E; Colhoun HM; Shore AC; Palombo C; Natali A; Edsfeldt A; Dunér P; Fredrikson GN; Björkbacka H; Östling G; Aizawa K; Casanova F; Persson M; Gooding K; Strain D; Khan F; Looker HC; Adams F; Belch J; Pinnoli S; Venturi E; Kozakova M; Gan LM; Schnecke V; Nilsson J;
Arterioscler Thromb Vasc Biol; 2015 Jul; 35(7):1723-31. PubMed ID: 25953645
[TBL] [Abstract][Full Text] [Related]
29. Influence of proteolytic-antiproteolytic enzymes and prooxidative-antioxidative factors on proteoglycan alterations in children with juvenile idiopathic arthritis.
Winsz-Szczotka K; Komosińska-Vassev K; Kuźnik-Trocha K; Gruenpeter A; Lachór-Motyka I; Olczyk K
Clin Biochem; 2014 Jun; 47(9):829-34. PubMed ID: 24495859
[TBL] [Abstract][Full Text] [Related]
30. Alterations in peripheral blood levels of TIMP-1, MMP-2, and MMP-9 in patients with type-2 diabetes.
Lee SW; Song KE; Shin DS; Ahn SM; Ha ES; Kim DJ; Nam MS; Lee KW
Diabetes Res Clin Pract; 2005 Aug; 69(2):175-9. PubMed ID: 16005367
[TBL] [Abstract][Full Text] [Related]
31. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
32. Circulating levels of MMP-1, -2, -3, -9, and TIMP-1 are increased in POEMS syndrome.
Michizono K; Umehara F; Hashiguchi T; Arimura K; Matsuura E; Watanabe O; Fujimoto N; Okada Y; Osame M
Neurology; 2001 Mar; 56(6):807-10. PubMed ID: 11274326
[TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT).
Tayebjee MH; Nadar S; Blann AD; Gareth Beevers D; MacFadyen RJ; Lip GY
Am J Hypertens; 2004 Sep; 17(9):764-9. PubMed ID: 15363817
[TBL] [Abstract][Full Text] [Related]
34. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
[TBL] [Abstract][Full Text] [Related]
35. Gelatinases and their tissue inhibitors in a group of subjects with metabolic syndrome.
Hopps E; Lo Presti R; Montana M; Noto D; Averna MR; Caimi G
J Investig Med; 2013 Aug; 61(6):978-83. PubMed ID: 23661104
[TBL] [Abstract][Full Text] [Related]
36. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia.
Beaudeux JL; Giral P; Bruckert E; Bernard M; Foglietti MJ; Chapman MJ
Atherosclerosis; 2003 Jul; 169(1):139-46. PubMed ID: 12860260
[TBL] [Abstract][Full Text] [Related]
37. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
Lorenzl S; Buerger K; Hampel H; Beal MF
Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
[TBL] [Abstract][Full Text] [Related]
38. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
39. Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy.
Tziakas DN; Chalikias GK; Papaioakeim M; Hatzinikolaou EI; Stakos DA; Tentes IK; Papanas N; Kortsaris A; Maltezos E; Hatseras DI
Am J Cardiol; 2005 Nov; 96(10):1449-51. PubMed ID: 16275197
[TBL] [Abstract][Full Text] [Related]
40. Dynamic regulation of plasma matrix metalloproteinases in human diabetic ketoacidosis.
Woo M; Patterson EK; Cepinskas G; Clarson C; Omatsu T; Fraser DD
Pediatr Res; 2016 Feb; 79(2):295-300. PubMed ID: 26492282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
